PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute to Corm 1449/APTO Complete if Known **Application Number** 09/857,739 June 8, 2001 Filing Date **INFORMATION DISCLOSURE** First Named Inventor Robertson et al.

STATEMENT BY APPLICANT **Group Art Unit** 1642 (use as many sheets as necessary **Examiner Name** Misook Yu, Ph.D. 02332-0020 (49409/284704) **Attorney Docket Number** Sheet | 1 of | 3

U.S. PATENT DOCUMENTS									
U.S. Patent Document Date of Publication of Pages, (
Examiner Initials	Cite No.¹	Number	Kind Code ² (If known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear			
									
				·····					
- 									
			- - 						
									
									
<u> </u>									
					<u> </u>				

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foi Office ³	reign Patent Docu Number ⁴	ment Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7
MY	1	W	O 96/03502	A2	Ramot University Authority for Applied Research and Industrial Development Ltd.	02-08-1996		
	2	W	O 99/58978	A2	University of Nottingham	11-18-1999		
V	3	W	O 00/26668	3	The Regents of the University of Michigan	05-11-2000		

Examiner	Date	
Signature	Considered	

Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

SEP 1 9 2006

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

			Complete if Known			
Substitute f	or Form 1449/A/PTO		Application Number	09/857,739		
INFORMATION DISCLOSURE		Filing Date	June 8, 2001			
-			First Named Inventor	Robertson et al.		
	STATEME	NT BY APPLICANT	Group Art Unit	1642		
(use as many sheets as necessary		Examiner Name	Misook Yu, Ph.D.			
Sheet	2	of 3	Attorney Docket Number	02332-0020 (49409/284704)		

			OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examine Initials	er (Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	. 4	1	APARECIDA et al., "Value of CEA Level Determination in Gallbladder Bile in the	
MY			Diagnosis of Liver Metastases Secondary to Colorectal Adenocarcinoma", Sao Paulo	
1			Medical Journal, 2001, Volume 119, No. 3, pp. 110-113.	l
	5	5	APOSTOLOPOULOS et al., Nature Medicine, 1998, Vol. 4, pp. 315-320.	
	ϵ	3	BAECHSTROM, et al., "Purification and Characterization of Sialyl-Le - Carrying Mucins	
		1	of Human Bile; Evidence for the Presence of MUC1 and MUC3 Apoproteins", The Journal	
			of Biological Chemistry, 1994, Volume 269, No. 20, pp. 14430-14437.	
	7	7	BEATTY, et al., "Biochemical Characterization of the Soluble Form of Tumor Antigen	
\mathbf{W}	/		MUC1 Isolated from Sera and Ascites Fluid of Breast and Pancreatic Cancer Patients",	
•		ĺ	Clinical Cancer Research, 2001, Vol. 7, pp. 781-787.	
	- 6	3	BEN-MAHREZ et al., British Journal of Cancer, 1988. No copy, not able to find with	MAP
	9	9	HEHIR et al., Journal of Surgical Oncology, 1993, Vol. 54, pp. 207-210.	
	1	10	HILL et al., "Nature of Carcinoembryonic Antigen Purified From Malignant Ascitic Fluid of	
MY			Serous Cystadenocarcinoma of the Ovary', Molecular Immunology, 1981, Vol. 18, No. 7,	
. 1	ı	1	pp. 647-653.	
	1	11	KARANIKAS, et al. J Clin Invest 1997 December 1, Vol. 100, No. 11, pp. 2783-2792.	
	1	12	KURALAY, et al., "Diagnostic Usefulness of Tumour Marker Levels in Pleural Effusions of	
1	1	- 1	Malignant and Benign Origin, Clinica Chimica Acta, 2000, Vol. 300, pp. 43-55.	
	1	13	LAFOND, R.E., et al., "Autoantibodies to c-myc protein: elevated levels in patients with	
			African Burkitt's lymphoma and normal Ghanians", Autoimmunity, vol. 13, no. 3, 1992, pp.	
	1	- 1	215-224.	
		14	LAI, et al., "Presence of Serum Anti-P53 Antibodies is Associated with Pleural Effusions	
			and Poor Prognosis in Lung Cancer Patients", Clinical Cancer Research, 1998, Vol. 4, pp.	
			3025-3030.	
	1	15	LAWNICZAK, et al., "The Search for Tumor-Associated Proteins in Pleural Effusions by	
			Means of Monoclonal Antibodies and a Dot Blot Assay", Lung, 1992, Vol. 170, pp. 65-74.	L
	1	16	MONTENARH, et al., "P53 Autoantibodies in the Sera, Cyst and Ascitic Fluids of Patients	
			with Ovarian Cancer", International Journal of Oncology, 1998, Vol. 13, pp. 605-610.	
	1	17	NERY, et al., "Isolation and Partial Characterization of Macromolecular Urinary Aggregates	
			Containing Carcinoembryonic Antigen-Like Activity", Br J. Cancer, 1974, Vol. 29, No. 413,	<u></u>
	1	18	NUSTAD et al., "Epitopes on CA 125 from Cervical Mucus and Ascites Fluid and	
•	I / I		Characterization of Six New Antibodies", pp. 303-314.	1

·			
Examiner	·	Date	•
Signature		Considered	

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

**			rescuestive of rece, the personne are	Complete if Known		
Substitute t	for Form 1449/A/PTO			Application Number	09/857,739	
INFORMATION DISCLOSURE				Filing Date	June 8, 2001	
	-			First Named Inventor	Robertson	
STATEMENT BY APPLICANT (use as many sheets as necessary				Group Art Unit	1642	
				Examiner Name	Misook Yu, Ph.D.	
Sheet	3	of	3	Attorney Docket Number	02332-0020 (49409/284704)	

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Initials No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²		
MY	19	PAVELIC et al., Anticancer Reasearch, 1991, Vol. 11, pp. 1421-1428.			
	20	RUSCIANO, "Concomitant Purification of Prostatic Carcinoma Tumor Markers from			
	ł	Human Seminal Fluid Under Nondenaturing Conditions", Clinical Chemistry, 1988, Vol. 34,			
		No. 12, pp. 2528-2532.			
	21	SANDRIN et al., Glycoconjugate Journal, 1997, Vol. 14, pp. 97-105.			
	22	SCHNEIDER, J. "P53 Protein, EGF Receptor, and Anti-P53 Antibodies in Serum from			
		Patients with Occupationally Derived Lung Cancer", British Journal of Cancer, 1999, Vol.			
		80, No. 12, pp. 1987-1994.			
	23	SHIBATA, et al., "Purification and Characterization of Prostate Specific Antigen from			
		Human Urine", Biochimica et Biophysica Acta, 1997, Vol. 1336, pp. 425-433.			
	24	SOKOLOFF, et al., "A Dual-Monoclonal Sandwich Assay for Prostate-Specific Membrane	,		
		Antigen: Levels in Tissues, Seminal Fluid and Urine", The Prostate, 2000, Vol. 43, pp. 150-			
		157.			
	25	STUBBS, et al., "Faecal Carcinoembryonic Antigen (CEA) in Patients with Large Bowel			
		Cancer', European Journal of Surgical Oncology, 1987, Vol. 13, pp. 433-436.			
	26	TONDINI, et al., "Comparison of CA15-3 and Carcinoembryonic Antigen in Monitoring the			
		Clinical Course of Patients with Metastatic Breast Cancer", Cancer Research, 1988, Vol. 48,	1		
	·	No. 14, pp. 4107-4112.			
	27	TOTH, et al., "A Carcinoembryonic Antigen (CEA) Binding Protein From Ascites			
		Influences CEA Uptake by Macrophages", 1990, Vol. 171, No. 2, pp. 633-640.			
	28	VENEGAS, et al., "Purificaton and Immunochemical Characterization of Ascitic Fluid			
		Glycoproteins Containing Certain Tumor-Associated and Blood Group Antigen Markers",			
		Glycoconjugate Journal, 1989, Vol. 6, pp. 511-524.			
	29	VOLKMANN, M., et al., "Anti-p53 autoantibodies as serological marker in different tumor-			
		entities", Clinical Chemistry, Volume 41, no. S6 part 2, 1995, pp. S221-S222			
	30	WOLF, et al., "A Tumour-Associated Antigen from The Pleural Effusion of Patients with			
		Squamous-Cell Carcinoma of Lung", Br. J. Cancer, 1978, Vol. 36, pp. 1046-1052.			
	31	YAMAMOTO et al., "L-Myc Overexpression and Detection of Auto-Antibodies Against L-			
V		Myc in Both the Serum and Pleural Effusion from a Patient with Non-Small Cell Lung			
		Cancer", Internal Medicine, 1997, Vol. 36, No. 10, pp. 724-727.			

Examiner	/Misook Yu/	Date	12/06/2006
Signature	/MIBOOK Tu/	Considered	

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.